Skip to main content
Premium Trial:

Request an Annual Quote

ActivX Biosciences Appoints Former Bayer Exec as VP of Chemistry

NEW YORK, May 24 - Proteomics startup ActivX Biosciences has appointed David Campbell, formerly director of discovery chemistry at Bayer, to the position of vice president of chemistry, the company said Thursday. 

At ActivX Campbell will be responsible for overseeing all chemistry programs at the company. 

Prior to working for Bayer, where he directed target discovery research in cancer and obesity, Campbell served as director of chemistry at Affymax Research Institute, a company with expertise in combinatorial chemistry and high-throughput screening.

"David Campbell is one of the new breed of young leaders in pharmaceutical chemistry," John Kozarich, ActivX's president and chief scientific officer, said in a statement. "His considerable accomplishments in the arenas of biotechnology and big pharma give him a unique perspective on discovery at the interface of chemistry and biology. He will be a major force in the application of ActivX chemistry to proteomics."

ActivX was founded last year by Robert Hillman, the company's CEO; Ben Cravatt, a faculty member at the Scripps Research Institute; and Jeffrey Smith, a member of the Burnham Institute. The company is developing a high-throughput platform for discovering medically-relevant proteins.  
The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.